Talvesta talotrexin: Phase I/II start

Next quarter, HNAB will begin the Phase I portion of an open-label, Phase I/II trial. In the Phase I portion, 15-20 patients with solid tumors will receive Talvesta once every 3 weeks. Pending positiv...